DrugPatentWatch Database Preview
Litigation Details for GENENTECH, INC. v. CELLTRION, INC. (D.N.J. 2018)
» See Plans and Pricing
GENENTECH, INC. v. CELLTRION, INC. (D.N.J. 2018)
| Docket | Start Trial | Date Filed | 2018-01-12 |
| Court | District Court, D. New Jersey | Date Terminated | 2018-11-01 |
| Cause | 15:1126 Patent Infringement | Assigned To | Renee Marie Bumb |
| Jury Demand | Plaintiff | Referred To | Karen M. Williams |
| Parties | BIOGEN, INC.; CELLTRION HEALTHCARE CO., LTD.; CELLTRION, INC.; CITY OF HOPE; GENENTECH, INC.; HOFFMANN-LA ROCHE INC.; TEVA PHARMACEUTICALS INTERNATIONAL GMBH; TEVA PHARMACEUTICALS USA, INC. | ||
| Patents | 7,381,560; 7,485,704; 7,807,799; 7,820,161; 7,976,838; 8,206,711; 8,329,172; 8,545,843; 8,557,244; 8,821,873; 9,296,821; 9,504,744 | ||
| Attorneys | CHRISTINE INTROMASSO GANNON; KEITH J. MILLER; LIZA M. WALSH; MICHAEL JAMES GESUALDO; WILLIAM T. WALSH , JR | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in GENENTECH, INC. v. CELLTRION, INC.
The biologic drugs covered by the patents cited in this case are Start Trial , Start Trial , Start Trial , Start Trial , and Start Trial .
Details for GENENTECH, INC. v. CELLTRION, INC. (D.N.J. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-07-05 | 46 | Amended Complaint | • U.S. Patent No. 7,381,560 84. U.S. Patent No. 7,381,560 (“the ’560 patent”) is entitled…DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 7,381,560) 148. Plaintiffs re-allege… COUNT 23 (INFRINGEMENT OF U.S. PATENT NO. 7,381,560 UNDER 35 U.S.C. § 271(E)(2)) …• U.S. Patent No. 6,489,447 78. U.S. Patent No. 6,489,447 (“the ’447 patent”) is entitled…• U.S. Patent No. 6,610,516 80. U.S. Patent No. 6,610,516 (“the ’516 patent”) is entitled | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
